This morning, President Trump signed a monumental Executive Order aiming to reduce prescription drug prices in the United States by as much as 30% to 80%. At the heart of this order is the revival of a "Most Favored Nation" (MFN) policy. This policy would mandate that Medicare pays no more for certain prescription drugs, specifically those administered in a doctor's office and covered under Medicare Part B, than the lowest price paid by any other economically comparable nation. This initiative revisits a similar proposal from President Trump's first term, which was ultimately blocked by legal challenges and later rescinded. However, the legal landscape has shifted with the passage of the Inflation Reduction Act (IRA) in 2022, which granted Medicare the authority to negotiate prices for a select number of drugs, potentially removing previous barriers to an MFN-style policy.
In addition to the MFN policy, the Executive Order outlines goals to increase transparency, stabilize Medicare Part D premiums, and address pricing gaps like the "pill penalty." It also calls for new Medicare and Medicaid models aimed at improving the value of high-cost drugs and refining payment and rebate systems.
Pharmaceutical manufacturers are already operating in a landscape shaped by growing scrutiny on drug pricing and shifting regulatory demands. This new Executive Order adds another layer of complexity, making it even more important to stay agile, streamline operations, and anticipate what’s coming next.
Proposed price controls like the MFN policy could significantly impact how pharmaceutical companies operate and generate revenue. In a market that has historically been less regulated, introducing these changes may mean a noticeable drop in income for manufacturers. The effects of regulation like this are complex. It could delay drug launches, restrict availability, and reduce competition, especially for generics. To stay competitive, manufacturers will need to sharpen every part of their business from how they run clinical trials to how they manage supply chains, navigate access hurdles, and bring products to market.
In this evolving and challenging landscape, the value of a dedicated, strategic partner becomes clear. D2 Solutions is uniquely positioned to assist pharmaceutical manufacturers in navigating these complexities, enhancing operational efficiency, driving revenue and ensuring continued patient access.
Since 2008, D2 Solutions has supported over 120 specialty pharmacy buildouts, partnered with more than 500 healthcare organizations, and guided 350+ successful product launches. Our credibility is grounded in experience, our solutions are built to scale, and our approach is guided by a deep understanding of what it takes to succeed across the full commercialization continuum.
Our support is focused on solving three of the industry’s most urgent challenges: distribution and operations, reimbursement, and patient services. We enable efficient distribution strategies that ensure products are available where and when patients need them, while minimizing access barriers for providers. On the reimbursement front, we support manufacturers in defining and executing payer strategies that maximize coverage and accelerate time to therapy, directly impacting revenue. Additionally, our patient service capabilities, including our UltraTouch® solutions, are custom designed to streamline access, reduce abandonment, and support long-term adherence. Together, these integrated services provide manufacturers with a commercialization framework that drives financial performance, operational efficiency, and measurable outcomes in an increasingly demanding market.
Interested in discussing how this executive order may impact your organization? Reach out. We look forward to connecting with you!